Irbesartan + Hidroclorotiazida Basi (Hydrochlorothiazide, Irbesartan)

Irbesartan/HCTZ acts on the renin‑angiotensin‑aldosterone system and fluid balance to control elevated blood pressure.

• Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension.
• Resistant hypertension: adds diuretic effect when an ARB alone does not achieve target blood pressure.
• Cardiovascular risk reduction: contributes to decreased risk of stroke and myocardial infarction in hypertensive individuals.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, which reduces peripheral resistance. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing extracellular fluid volume. The combined actions result in additive blood‑pressure‑lowering effects.

Adverse reactions may occur with any medication. The following list reflects reported events.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Increased urination: more frequent need to void.

Serious or Rare Side Effects

• Severe dehydration: excessive fluid loss requiring medical attention.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: elevated blood potassium levels that can affect heart rhythm.
• Anaphylactic reaction: severe allergic response requiring emergency care.

Before initiating therapy, consider the following safety measures.

• Monitor renal function: assess serum creatinine and eGFR regularly.
• Assess electrolytes: watch for hyponatremia, hypokalemia, or hyperkalemia.
• Avoid in severe hepatic impairment: use only if benefits outweigh risks.
• Pregnancy: risk category unknown; avoid unless clearly needed.
• Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan/HCTZ can interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use may increase renal risk.
• Dual RAAS blockade (e.g., ACE inhibitors, other ARBs): may cause excessive hypotension or kidney injury.
• Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect kidney function.
• Lithium: concurrent use can raise lithium concentrations, risking toxicity.